Citigroup’s Estrella Immunopharma ESLA Stock Holding History

Citigroup’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-48,825	Closed	-$502K	–	5596
2022 Q4	$502K	Sell	48,825 -13,210	-21%	-$134K	﹤0.01%	3163
2022 Q3	$624K	Hold	62,035	–	–	﹤0.01%	3069
2022 Q2	$620K	Hold	62,035	–	–	﹤0.01%	3048
2022 Q1	$620K	Buy	+62,035	New	+$618K	﹤0.01%	3358

Other funds holding ESLA

HHGC

Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

RCM

Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

SOA

Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Citigroup's ESLA Position: Q1 2023 in Review

Citigroup sold out of Estrella Immunopharma (ESLA) in Q1 2023, closing a stake of 48,825 shares — an estimated $502K sold.

Citigroup first reported a position in ESLA in Q1 2022 and held it in 4 quarters. The position peaked at $624K in Q3 2022. 8 funds tracked by Wall St. Rank hold ESLA as of Q1 2023.

Citigroup reported no remaining Estrella Immunopharma position as of Q1 2023 after selling out during the quarter.
Citigroup sold 48,825 Estrella Immunopharma shares in Q1 2023, an estimated $502K.
Citigroup first reported a position in Estrella Immunopharma in Q1 2022 and held it in 4 quarters.
Citigroup's Estrella Immunopharma position peaked at $624K in Q3 2022.
8 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.